All In Biotech

Drug Trial Radar · NCT05944978

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Phase Ib/II Clinical Study of GNC-035 Tetra-specific Antibody Injection in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Last checked: Nov 19, 2026Latest source record: Sep 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

3

Actual

Start

Aug 16, 2023

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Sponsor type
Industry
First posted
Jul 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, multicenter, phase Ib/II clinical trial was conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of GNC-035 quad-specific antibody injection in patients with relapsed or refractory chronic lymphocytic leukemia and other hematological malignancies

Conditions

  • Relapsed/Refractory Chronic Lymphocytic Leukemia

Interventions

  • GNC-035Drug

    GNC-035 was intravenously infused 2h to 4h, once a week (IV, QW), and a 3-week cycle was used.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib: Dose limiting toxicity (DLT)Time frame: Up to 21 days after the first dose
  2. Phase Ib: Maximum tolerated dose (MTD)Time frame: Up to 21 days after the first dose
  3. Phase Ib: Treatment-Emergent Adverse Event (TEAE)Time frame: Up to approximately 24 months
  4. Phase Ib: Recommended Phase II Dose (RP2D)Time frame: Up to 21 days after the first dose
  5. Phase II: Objective Response Rate (ORR)Time frame: Up to approximately 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.